H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target The firm views the early results results from Fate’s FT819 in 10 heavily pretreated systemic lupus erythematosus patients as “encouraging.” The firm cites the results and the stock’s valuation for the upgrade.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Is FATE a Buy, Before Earnings?
- Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
- Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
- Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
- Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7